Steve O'Loughlin - 31 Mar 2025 Form 4 Insider Report for Actinium Pharmaceuticals, Inc. (ATNM)

Role
Chief Financial Officer
Signature
/s/ Steve O'Loughlin
Issuer symbol
ATNM
Transactions as of
31 Mar 2025
Net transactions value
$0
Form type
4
Filing time
02 Apr 2025, 18:20:36 UTC
Previous filing
29 Dec 2023
Next filing
04 Mar 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -3,333 -100% $0.000000 0 31 Mar 2025 Common Stock 3,333 $53.70 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -1,666 -100% $0.000000 0 31 Mar 2025 Common Stock 1,666 $59.70 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -3,333 -100% $0.000000 0 31 Mar 2025 Common Stock 3,333 $41.70 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -8,833 -100% $0.000000 0 31 Mar 2025 Common Stock 8,833 $23.49 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -13,333 -100% $0.000000 0 31 Mar 2025 Common Stock 13,333 $6.96 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -59,066 -100% $0.000000 0 31 Mar 2025 Common Stock 59,066 $9.55 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -107,463 -100% $0.000000 0 31 Mar 2025 Common Stock 107,463 $6.07 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -256,438 -100% $0.000000 0 31 Mar 2025 Common Stock 256,438 $4.96 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -253,123 -100% $0.000000 0 31 Mar 2025 Common Stock 253,123 $5.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration.